LIGAND PHARMACEUTICALS INCORPORATED Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value
LIGAND PHARMACEUTICALS INCORPORATED (LGNZZ) had Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value of $5.25 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue · last filed 2026-08-07
- 2026-06-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $5.25M.
- 2026-03-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $5.21M.
- 2025-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $4.99M.
- 2025-09-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $9.35M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value as first filed |
|---|---|---|
| 2026-06-30 | $5.25M 10-Q · filed 2026-08-07 | |
| 2026-03-31 | $5.21M 10-Q · filed 2026-05-08 | |
| 2025-12-31 | $4.99M 10-Q · filed 2026-08-07 | |
| 2025-09-30 | $9.35M 10-Q · filed 2025-11-07 | |
| 2025-06-30 | $17.96M 10-Q · filed 2025-08-08 | |
| 2025-03-31 | $18.03M 10-Q · filed 2025-05-09 | |
| 2024-12-31 | $9.78M 10-K · filed 2026-02-27 | $10.58M 10-K · filed 2025-02-28 |
| 2024-09-30 | $30.38M 10-Q · filed 2024-11-08 | |
| 2024-06-30 | $54.65M 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $3.73M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $3.53M 10-K · filed 2026-02-27 | |
| 2022-12-31 | $135.00K 10-K · filed 2025-02-28 | |
| 2021-12-31 | $409.00K 10-K · filed 2024-02-29 | |
| 2018-12-31 | $0.00 10-K · filed 2019-02-28 | |
| 2017-12-31 | $3.88M 10-K · filed 2019-02-28 | |
| 2016-12-31 | $3.21M 10-K · filed 2018-03-01 | |
| 2016-09-30 | $3.21M 10-Q · filed 2016-11-14 | |
| 2016-06-30 | $3.21M 10-Q · filed 2016-11-14 | |
| 2016-03-31 | $4.77M 10-Q · filed 2016-11-14 | |
| 2015-12-31 | $4.78M 10-K · filed 2017-02-28 | |
| 2015-09-30 | $5.55M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $5.55M 10-Q · filed 2015-08-05 | |
| 2015-03-31 | $88.00K 10-Q · filed 2015-05-11 | |
| 2014-12-31 | $322.00K 10-K · filed 2016-11-14 | $11.75M 10-K · filed 2014-12-01 |
| 2014-09-30 | $523.00K 10-Q · filed 2014-10-31 | |
| 2014-06-30 | $804.00K 10-Q · filed 2014-08-05 | |
| 2014-03-31 | $1.14M 10-Q · filed 2014-05-07 | |
| 2013-12-31 | $11.75M 10-K · filed 2015-02-23 | |
| 2013-09-30 | $16.52M 10-Q · filed 2013-11-08 | |
| 2013-06-30 | $15.87M 10-Q · filed 2013-08-01 | |
| 2013-03-31 | $14.77M 10-Q · filed 2013-05-08 | |
| 2012-12-31 | $13.96M 10-K/A · filed 2014-12-12 | $12.53M 10-K · filed 2013-03-14 |
| 2011-12-31 | $21.45M 10-K · filed 2013-03-14 | |
| 2010-12-31 | $30.89M 10-K · filed 2013-03-14 |